Use of prostaglandin (PGE2) receptor a (EP4) selective agonists for the treatment of acute and chronic renal failure
AssigneePfizer Inc.
InventorsVishwas M. Paralkar, David D. Thompson
Life of this patent
Estimating the term…
Abstract
This invention is directed to methods and compositions of treating acute or chronic renal failure or dysfunction, or conditions caused thereby, comprising administering prostaglandin agonists, which are EP4 receptor selective prostaglandin agonists.
Claims16
A method of treating acute or chronic renal failure or dysfunction in a mammal comprising administering to said mammal about 0.001 mg/kg/day to about 100 mg/kg/day of an EP4 receptor selective agonist, an isomer thereof, a prodrug of said agonist or isomer, or a pharmaceutically acceptable salt of said agonist, isomer or prodrug, provided said acute or chronic renal dysfunction is not nephritis and further provided said acute or chronic renal failure or dysfunction is not the result of hypertension.
A method of treating acute or chronic renal failure or dysfunction in a mammal comprising administering to said mammal about 0.001 mg/kg/day to about 100 mg/kg/day of an EP4 receptor selective agonist of formula I:
- an isomer thereof, a prodrug of said agonist or isomer, or a pharmaceutically acceptable salt of said agonist, isomer or prodrug, wherein:
- Q is COOR3, CONHR4 or tetrazol-5-yl;
- A is a single or cis double bond;
- B is a single or trans double bond;
- ═U is
- R2 is α-thienyl, phenyl, phenoxy, monosubstituted phenyl or monosubstituted phenoxy, said substituents being selected from the group consisting of chloro, fluoro, phenyl, methoxy, trifluoromethyl and (C1-C3)alkyl;
- R3 is hydrogen, (C1-C5)alkyl, phenyl or p-biphenyl;
- R4 is COR5 or SO2R5;
- and
- R5 is phenyl or (C1-C5)alkyl.
A method of treating acute or chronic renal failure or dysfunction in a mammal comprising administering to said mammal a pharmaceutical composition, said composition comprising about 0.001 mg/kg/day to about 100 mg/kg/day of a selective EP4 receptor agonist, an isomer thereof, a prodrug of said agonist or isomer, or a pharmaceutically acceptable salt of said agonist, isomer or prodrug, together with a physiologically acceptable diluent, carrier or vehicle, provided said acute or chronic renal dysfunction is not nephritis and further provided said acute or chronic renal failure or dysfunction is not the result of hypertension.
A method of treating acute or chronic renal failure or dysfunction in a mammal comprising administering to said mammal a pharmaceutical composition, said composition comprising about 0.001 mg/kg/day to about 100 mg/kg/day of an EP4 receptor selective agonist of formula I:
- an isomer thereof, a prodrug of said agonist or isomer, or a pharmaceutically acceptable salt of said agonist, isomer or prodrug, wherein:
- Q is COOR3, CONHR4 or tetrazol-5-yl;
- A is a single or cis double bond;
- B is a single or trans double bond;
- ═U is
- R2 is α-thienyl, phenyl, phenoxy, monosubstituted phenyl or monosubstituted phenoxy, said substituents being selected from the group consisting of chloro, fluoro, phenyl, methoxy, trifluoromethyl and (C1-C3)alkyl;
- R3 is hydrogen, (C1-C5)alkyl, phenyl or p-biphenyl;
- R4 is COR5 or SO2R5;
- and
- R5 is phenyl or (C1-C5)alkyl,
- together with a physiologically acceptable diluent, carrier or vehicle.
Dependencies are inferred from the claim text.